455 Mission Bay Blvd South
221 articles with Twist Bioscience
Twist Bioscience Corporation announced that Steffen Hellmold, senior vice president, business development for data storage, will participate in the 2022 Materials Research Society Spring Meeting and Exhibit taking place in Honolulu, Hawai’i May 8-13 and virtually May 23-25.
Twist Bioscience and Astellas Pharma have entered into a collaboration to identify therapeutic antibodies to reduce tumor microenvironment-mediated immunosuppression.
Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
Twist Bioscience Corporation today announced it has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc.
Twist Bioscience Corporation reported financial results and business highlights for the second quarter of fiscal 2022 ended March 31, 2022.
Twist Bioscience Highlights Synthetic Libraries and High Throughput Antibody Discovery Platform at PEGS Boston 2022
Twist Bioscience Corporation today announced six poster presentations at PEGS (The Essential Protein Engineering & Cell Therapy Summit) Boston occurring May 2-6 virtually and in-person at the Hynes Convention Center in Boston, MA.
Twist Bioscience Corporation announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.
Twist Bioscience Corporation today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development.
Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies
Twist Bioscience Corporation and MediSix Therapeutics today announced a collaboration to discover novel antibodies against five undisclosed targets.
Twist Bioscience Corporation and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem.
Twist Bioscience Launches Synthetic RNA Positive Controls for SARS-CoV-2 Encapsulated in Imagene’s Stainless Steel Capsules
Twist Bioscience Corporation today announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in proprietary stainless steel minicapsules provided by Imagene SA.
The Business Intelligence Group today announced that it has awarded Abveris a division of Twist Bioscience, a Best Places to Work 2022.
Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
Twist Bioscience Corporation and Kriya Therapeutics, Inc. today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications.
Kriya forged an antibody discovery agreement with Twist to support the delivery of antibodies with AAV gene therapy in therapeutic oncology applications.
Twist Bioscience Corporation announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the following upcoming virtual investor conferences:.
Twist Bioscience Corporation today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.
Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Twist Bioscience Corporation today announced the closing of its upsized underwritten public offering of 5,227,272 shares of its common stock at a public offering price of $55.00 per share.
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00 per share.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it intends to offer and sell in an underwritten public offering up to $200 million of shares of its common stock.
Twist Bioscience Corporation and Eleven Therapeutics today announced that they have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening as well as vaccine and therapeutic development.